Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Company intelligence / Profile preview
Harbin First Pharmaceutical, a core subsidiary of the Harbin Pharmaceutical Group (Hayao), is a major Chinese pharmaceutical manufacturer based in Heilongjiang province. The company specializes in the production of traditional Chinese medicines (TCM), chemical generics, and high-volume injectable formulations. It is particularly well-known for its flagship product, Shuanghuanglian, which is widely used in China for treating respiratory infections. The company operates large-scale, GMP-certified manufacturing facilities that supply both domestic and international markets with antibiotics, cardiovascular drugs, and nutritional supplements. As a key player in the Chinese healthcare sector, it integrates traditional herbal expertise with modern chemical synthesis and sterile manufacturing processes.
Beyond the preview
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Follow clinical development from trial design and recruitment through results.
Explore licensing agreements, acquisitions, and the assets behind each deal.
Trace financing activity and the investors behind a company’s development.
Compare peer pipelines by target, modality, and therapeutic area.
Explore technology platforms and the patent landscape around relevant assets.
Connect company news and source material to the questions you’re investigating.
See how Gosset can support your research on Harbin First Pharmaceutical.